On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future

Published:2022-08-10 Issue:12 Volume:23 Page:1425-1444
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Sunder-Plassmann Vincent¹,Aksoy Osman¹,Lind Judith¹,Pecherstorfer Martin²,Vallet Sonia¹²,Podar Klaus¹²

Affiliation:

1. Molecular Oncology and Hematology Unit, Karl Landsteiner University of Health Sciences. Dr. Karl-Dorrek-Straße 30, 3500 Krems an der Donau, Austria

2. Department of Internal Medicine 2, University Hospital Krems, Mitterweg 10, 3500 Krems an der Donau, Austria

Funder

Life Science

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2101362

Reference139 articles.

1. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

2. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma

3. Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma

4. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2 as a potential therapeutic target on quiescent prostate cancer cells;Translational Oncology;2023-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP